pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,561 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1890Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13094Rare Disease3387Immunology3069Cardiology2866Hematology2335Pulmonology2299
  • RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer data
    RevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
    BioSpace · 7h agoPositive readoutPositive↗ source
  • Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory market
    Analysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
    BioSpace · 7h agoDealPositive
← prev
page 1 of 223
next →
123
fda medwatch118
globenewswire health73
fda press62
Vaccines1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
↗ source
  • Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
    Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
    Fierce Biotech · 14h agoPositive readoutPositive↗ source
  • Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competition
    Revolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…
    Endpoints · 5h agoPositive readoutNeutral↗ source
  • Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancer
    Merck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
    Endpoints · 6h agoPositive readoutPositive↗ source
  • Merck-Kelun ADC sac-TMT shows overall survival benefit in Phase 3 stomach cancer trial
    Merck, licensing the TROP2-targeting antibody drug conjugate sac-TMT from Kelun-Biotech, reported that the therapy improved overall survival in patients with advanced gastroesophageal adenocarcinom…
    BioSpace · 7h agoPositive readoutPositive↗ source
  • Lawmakers split on US restrictions for China biotech investments
    Ahead of the upcoming Democrat-controlled Congress, lawmakers from both parties are articulating new positions on whether the United States should limit investments in China's rapidly growing biote…
    Endpoints · 2h agoRegulatoryNeutral↗ source
  • FDA delays decision on Savara's rare lung disease therapy, pushing back deadline
    The FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
    BioSpace · 5h agoRegulatoryNegative↗ source
  • Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug prices
    Sanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…
    STAT · 7h agoDealNeutral↗ source
  • Celldex drops eczema antibody barzolvolimab after Phase 2 failure
    Celldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
    Endpoints · 9h agoNegative readoutNegative↗ source
  • FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are ranked
    The Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…
    STAT · 12h agoRegulatoryNeutral↗ source
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 12h agoRegulatoryNeutral↗ source
  • Heraeus Medevio issues recall of vascular guidewires over coating safety risk
    The FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…
    fda medwatch · 16h agoRegulatoryNegative↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 18h agoNegative readoutNegative↗ source
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 21h agoRegulatoryNegative↗ source
  • Novo announces layoff of 215 New Jersey staff as Bausch + Lomb trial misses endpoint
    Novo Pharma said it will cut 215 positions at its Plainsboro, New Jersey facility, with the reductions slated to begin in February 2027. The move adds to a series of recent workforce reductions ac…
    Endpoints · 5h agoLayoffsNegative↗ source
  • Alterome reports early Phase 1 data for KRAS-targeted therapy in pancreatic, lung and colon cancers
    Alterome has unveiled preliminary Phase 1 data for its experimental KRAS-targeted therapy. The drug is designed to hit a spectrum of KRAS mutations that drive several solid tumours. The early stud…
    STAT · 7h agoPositive readoutNeutral↗ source
  • Teva appoints interim R&D head as Eric Hughes departs
    Teva announced that its global research and development leader and chief medical officer, Eric Hughes, has left the company. Hughes, who joined Teva in 2022 after a senior role at Vertex, will be s…
    Endpoints · 9h agoNeutral↗ source
  • UnitedHealth sues CMS over lowered 2027 Medicare Advantage star ratings
    UnitedHealth Group has filed a lawsuit against the Centers for Medicare & Medicaid Services seeking to overturn the agency’s lowered star ratings for its Medicare Advantage plans for 2027. The sui…
    STAT · 14h agoRegulatoryNegative↗ source
  • FDA outlines inspection focus on risk management for combination product manufacturers
    FDA officials said that manufacturers using a streamlined CGMP approach for combination products should expect the agency to closely scrutinize their risk management activities. The remarks were d…
    raps · 21h agoRegulatoryNeutral↗ source
  • Medicare launches pilot to test nutrition and exercise programs as preventive care for chronic disease
    Department of Health and Human Services announced that fifteen groups across the United States will participate in a Medicare pilot aimed at evaluating lifestyle interventions for chronic disease p…
    STAT · 2h agoRegulatoryPositive↗ source
  • CNS players discuss deals, psychiatry challenges and Alzheimer focus at Jefferies London conference
    The Jefferies Global Healthcare conference in London brought together several companies active in the central nervous system and psychiatry sectors. Attendees heard updates from a range of drugmake…
    Endpoints · 9h agoNeutral↗ source
  • Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football players
    Researchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…
    STAT · 8h agoNeutral↗ source
  • Ailux appoints former Johnson & Johnson executive Lloyd Miller as chief medical officer
    Ailux announced the hiring of Lloyd Miller as its new chief medical officer. Miller comes from Johnson & Johnson where he served as senior vice president and global head of translational science &…
    STAT · 6h agoNeutral↗ source
  • Exercise should be prescribed alongside rest for concussion recovery, author argues
    The author recounts a severe brain injury that left him in a coma, caused significant muscle loss and left-side weakness, and made simple tasks like getting out of a bathtub a struggle. He began a…
    STAT · 12h agoPositive↗ source